Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INTESTIFORT is a broad-spectrum probiotic dietary supplement developed and manufactured by the Belgian company Sanifortpharma. The product contains a combination of eight complementary strains of lactic acid bacteria. Five of these strains are specifically selected for their role in supporting immune system function, while the other three are included to promote optimal digestion and maintain a healthy intestinal flora. INTESTIFORT is intended for oral administration to support intestinal comfort, regularity, and bowel movement consistency. It is also marketed for use during recovery after antibiotic treatment, to enhance the absorption of vitamins and minerals, and to improve energy production by optimizing the gut microbiome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on INTESTIFORT.